P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor
- Authors
- Kim, J.; Jang, W.J.; Lee, W.S.; Choi, K.H.; Lee, J.M.; Park, T.K.; Yang, J.H.; Choi, J.-H.; Song, Y.B.; Choi, S.-H.; Gwon, H.-C.; Lee, S.H.; Oh, J.-H.; Chun, W.J.; Park, Y.H.; Im, E.-S.; Jeong, J.-O.; Cho, B.R.; Oh, S.K.; Yun, K.H.; Cho, D.-K.; Lee, J.-Y.; Koh, Y.-Y.; Bae, J.-W.; Choi, J.W.; Yoon, H.J.; Lee, S.U.; Cho, J.H.; Choi, W.G.; Rha, S.-W.; Hahn, J.-Y.
- Issue Date
- Jul-2021
- Publisher
- BMJ Publishing Group
- Keywords
- clinical; coronary artery disease; percutaneous coronary intervention; pharmacology
- Citation
- Heart, v.107, no.13, pp 1077 - 1083
- Pages
- 7
- Journal Title
- Heart
- Volume
- 107
- Number
- 13
- Start Page
- 1077
- End Page
- 1083
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54107
- DOI
- 10.1136/heartjnl-2020-318821
- ISSN
- 1355-6037
1468-201X
- Abstract
- Objective: To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI). Methods: The Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents (SMART-CHOICE) randomised trial compared 3-month DAPT followed by P2Y12 inhibitor monotherapy with 12-month DAPT. In this trial, 2993 patients undergoing successful PCI with drug-eluting stent were enrolled in Korea. As a prespecified analysis, P2Y12 inhibitor monotherapy after 3-month DAPT versus 12-month DAPT were compared among patients receiving clopidogrel and those receiving potent P2Y12 inhibitor (ticagrelor or prasugrel), respectively. The primary endpoint was a composite of all-cause death, myocardial infarction or stroke at 12 months after the index procedure. Results: Among 2993 patients (mean age 64 years), 58.2% presented with acute coronary syndrome. Clopidogrel was prescribed in 2312 patients (77.2%) and a potent P2Y12 inhibitor in 681 (22.8%). There were no significant differences in the primary endpoint between the P2Y12 inhibitor monotherapy group and the DAPT group among patients receiving clopidogrel (3.0% vs 3.0%; HR: 1.02; 95% CI 0.64 to 1.65; p=0.93) as well as among patients receiving potent P2Y12 inhibitors (2.4% vs 0.7%; HR: 3.37; 95% CI 0.77 to 14.78; p=0.11; interaction p=0.1). Among patients receiving clopidogrel, P2Y12 inhibitor monotherapy compared with DAPT showed consistent treatment effects across various subgroups for the primary endpoint. Among patients receiving potent P2Y12 inhibitors, the rate of bleeding (Bleeding Academic Research Consortium types 2- 5) was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT group (1.5% vs 5.0%; HR: 0.33; 95% CI 0.12 to 0.87; p=0.03). Conclusions: Compared with 12-month DAPT, clopidogrel monotherapy after 3-month DAPT showed comparable cardiovascular outcomes in patients undergoing PCI. Trial registration number: NCT02079194. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/54107)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.